Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)
Journal article
HERRINGTON W. et al, (2023), Kidney International Reports
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Preprint
Horby PW. et al, (2023)
The Kidney Failure Risk Equation: Evaluation of Novel Input Variables including eGFR Estimated Using the CKD-EPI 2021 Equation in 59 Cohorts
Journal article
Grams ME. et al, (2023), Journal of the American Society of Nephrology : JASN, 34, 482 - 494
Mechanisms and Predictors of Acute Kidney Injury with Perioperative Rosuvastatin in Patients Undergoing Cardiac Surgery
Preprint
Wijesurendra RS. et al, (2023)
Interference of urinary albumin-to-creatinine ratio measurement by glycosuria: clinical implications when using SGLT-2 inhibitors.
Journal article
Chapman D. et al, (2023), Kidney Int
Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: A Mendelian Randomization Study.
Journal article
Donovan K. et al, (2023), Clin J Am Soc Nephrol, 18, 17 - 27
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
Journal article
Nuffield Department of Population Health Renal Studies Group None. and SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium None., (2022), Lancet, 400, 1788 - 1801
Adiposity and NMR-measured lipid and metabolic biomarkers among 30,000 Mexican adults.
Journal article
Aguilar-Ramirez D. et al, (2022), Commun Med (Lond), 2
Empagliflozin in Patients with Chronic Kidney Disease.
Journal article
EMPA-KIDNEY Collaborative Group None. et al, (2022), N Engl J Med
Mild-to-Moderate Kidney Dysfunction and Cardiovascular Disease: Observational and Mendelian Randomization Analyses.
Journal article
Gaziano L. et al, (2022), Circulation
Experiences of the Data Monitoring Committee for the RECOVERY trial, a large-scale adaptive platform randomised trial of treatments for patients hospitalised with COVID-19.
Journal article
Sandercock PAG. et al, (2022), Trials, 23
Determining the Relationship Between Blood Pressure, Kidney Function, and Chronic Kidney Disease: Insights From Genetic Epidemiology.
Journal article
Staplin N. et al, (2022), Hypertension
Development and Validation of Prediction Models of Adverse Kidney Outcomes in the Population With and Without Diabetes.
Journal article
Grams ME. et al, (2022), Diabetes Care, 45, 2055 - 2063
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
Journal article
RECOVERY Collaborative Group None., (2022), Lancet, 400, 359 - 368
Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial.
Journal article
EMPA-KIDNEY Collaborative Group None., (2022), Nephrol Dial Transplant, 37, 1317 - 1329
Allocated but not treated: the silent 16% - Authors' reply.
Other
Horby P. et al, (2022), Lancet, 399, 1775 - 1776
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
Preprint
RECOVERY Collaborative Group None. et al, (2022)
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Journal article
RECOVERY Collaborative Group None., (2022), Lancet, 399, 665 - 676
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Journal article
RECOVERY Collaborative Group None., (2022), Lancet, 399, 143 - 151